WASHINGTON, June 5 -- The Senate Judiciary Committee released the following testimony by Jocelyn Ulrich, vice president of policy and research at PhRMA, from a hearing dated May 21, 2024, entitled "Ensuring Affordable & Accessible Medications: Examining Competition in the Prescription Drug Market":

* * *

According to Harvard researchers, "the most insidious effect of 340B...is the incentive it gives clinics to prescribe high-cost medications, even whe . . .

Click here for more information about our products